Immunomodulating agents have a favourable long-term safety profile, making them an appropriate choice for both induction therapy and in strategies for de-escalation. Regardless of the treatment setting, patient satisfaction plays a critical role in compliance. This extract video will focus on guiding patients to a therapy they are most comfortable with, based on their perspective on potential benefits, risks, and convenience.

Before selecting a disease-modifying therapy, RRMS patients need to be well educated about their disease, goals of therapy and treatment options. This video features an expert’s opinion on how best to guide patients in selecting a high-efficacy RRMS treatment, based on their short-term and long-term goals as well as their risk tolerance.

This quick tour with leading gynecologic oncology experts focuses primarily on the real-world perspective on ovarian cancer, current treatment options and early diagnostic tools on the horizon. This program seeks to bridge the gap and build communication between all healthcare providers, including family physicians, gynecologists, and oncologists, with a focus on outcomes for patients with ovarian cancer.

The expansion of disease-modifying therapies (DMT) has facilitated the individualization of therapy for patients with RRMS. However, therapies with potent effects on immune function commonly impose risks, requiring a risk-benefit analysis. This extract video will evaluate the balance of efficacy against the safety and tolerability of various RRMS treatments.

Oral immunomodulators are widely regarded as comparably efficacious and safe relative to the injectable drugs. In addition to evaluating the balance of efficacy, safety and tolerability of first-line therapies, this extract video will also explore the importance of patient satisfaction as a clinical goal.

This eXtract video features key information from the GA2LEN UCARE Urticaria Conference. This quick tour with an expert focuses on the latest data and developments on urticaria. The engaging format is meant to highlight relevant topics as discussed at this year's GA2LEN UCARE conference and to foster spirited and productive conversations among the healthcare community.

This extract video features the expert opinion of Dr. Marcus Maurer on the international guidelines for chronic spontaneous urticaria (CSU) (also known as chronic idiopathic urticaria) and their implementation in Canadian practice. In this video, Dr. Maurer emphasizes the importance of making a prompt diagnosis and following the evidence-based treatment algorithm.

This eXtract video explores the challenges involved in the early identification of secondary-progressive multiple sclerosis (SPMS) and the necessity for timely diagnosis in order to ensure optimal management of the disease.

This eXtract video outlines the clinical features of food allergy versus chronic spontaneous urticaria (CSU). This quick tour with an expert focuses primarily on CSU and the prompt initiation of the evidence-based treatment algorithm in order to restore an acceptable quality of life. An emphasis will be placed on the key points of efficient diagnosis and treatment at the level of primary care. Specialist referrals for CSU patients inadequately controlled on first-line therapies should be for the purpose of advanced care instead of additional testing.

This eXtract video focuses on the key decision-making factors for selecting the initial first-line treatment in patients with mild-to-moderate RRMS. An emphasis will be placed on identifying suboptimal treatment outcomes and treatment failures along with the importance of a first-switch conversion when required.